Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company employs 10 full-time employees The company went IPO on 2021-07-16. The firm launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
Regencell Bioscience Holdings Ltd 最大收入来源是 Service Center Based Distribution,在最近的收益报告中收入为 3,014,348,000。就地区而言, United States 是 Regencell Bioscience Holdings Ltd 的主要市场,收入为 4,000,954,000。